Fintel reports that on January 13, 2026, Goldman Sachs upgraded their outlook for Arcus Biosciences (NYSE:RCUS) from Neutral to Buy.
Analyst Price Forecast Suggests 43.98% Upside
As of December 21, 2025, the average one-year price target for Arcus Biosciences is $32.74/share. The forecasts range from a low of $16.16 to a high of $49.35. The average price target represents an increase of 43.98% from its latest reported closing price of $22.74 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Arcus Biosciences is 311MM, an increase of 29.57%. The projected annual non-GAAP EPS is -3.66.
What is the Fund Sentiment?
There are 407 funds or institutions reporting positions in Arcus Biosciences. This is an decrease of 8 owner(s) or 1.93% in the last quarter. Average portfolio weight of all funds dedicated to RCUS is 0.12%, an increase of 21.28%. Total shares owned by institutions increased in the last three months by 0.50% to 111,122K shares. 
The put/call ratio of RCUS is 0.12, indicating a bullish outlook.
What are Other Shareholders Doing?
Gilead Sciences holds 31,425K shares representing 25.40% ownership of the company. No change in the last quarter.
Point72 Asset Management holds 4,332K shares representing 3.50% ownership of the company. In its prior filing, the firm reported owning 5,967K shares , representing a decrease of 37.72%. The firm increased its portfolio allocation in RCUS by 3.42% over the last quarter.
IJR - iShares Core S&P Small-Cap ETF holds 4,037K shares representing 3.26% ownership of the company. In its prior filing, the firm reported owning 4,235K shares , representing a decrease of 4.91%. The firm decreased its portfolio allocation in RCUS by 2.00% over the last quarter.
Woodline Partners holds 3,770K shares representing 3.05% ownership of the company. In its prior filing, the firm reported owning 4,000K shares , representing a decrease of 6.11%. The firm increased its portfolio allocation in RCUS by 40.31% over the last quarter.
Suvretta Capital Management holds 3,689K shares representing 2.98% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
